Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
Add more filters










Publication year range
1.
Int J Pharm ; 620: 121749, 2022 May 25.
Article in English | MEDLINE | ID: mdl-35427748

ABSTRACT

Drug-coated balloons (DCB) have emerged as the alternative procedure for restenosis because of their ability to treat a variety of occlusion types with a uniform dose of anti-proliferative drugs. DCB are balloons coated with antiproliferative drugs encapsulated in a polymer matrix. There are several types of coating matrices used to produce DCB. In this study, the relationship between coating composition and drug release under physiologically relevant conditions was examined to understand how differences in coating composition impacts the drug transfer from the balloon surface to the simulated body fluids. To conduct the experiments, the balloons were coated with different paclitaxel (drug)-to-iopromide (excipient) ratios (3:1, 3:2 and 1:2) using an in-house developed micro-pipetting method. Scanning electron microscopy (SEM) images showed that the 3:1 PTX:IOP ratio produced a more uniform, crystalline microstructure with a thinner coating throughout the balloon surface compared to the other drug-to-excipient ratios. The 1:2 PTX:IOP ratio showed the least crystalline microstructure among the three ratios evaluated in this study. Three different drug elution conditions were tested. The amount of drug released to the medium was quantified by high performance liquid chromatography (HPLC). Our soaking study and submerge & deploy study showed that ∼20% of the drug transferred to the target site under physiological conditions. A track and deploy method was performed using a "mock" artery, to simulate an in vitro environment. Coated balloons were passed through the mock artery to mimic tracking turns the balloon within the arteries during the angioplasty procedures. Seven elution samples were collected at different stages of the procedure. Drug release results suggest that the higher excipient ratio helps to deliver the lipophilic drug to the target site under simulated conditions but causes higher drug loss during the balloon transfer process.


Subject(s)
Antineoplastic Agents , Peripheral Arterial Disease , Antineoplastic Agents/therapeutic use , Coated Materials, Biocompatible/chemistry , Drug Liberation , Excipients/chemistry , Humans , Paclitaxel/chemistry , Peripheral Arterial Disease/drug therapy , Treatment Outcome
2.
Int J Pharm ; 554: 312-321, 2019 Jan 10.
Article in English | MEDLINE | ID: mdl-30395954

ABSTRACT

Drug coated balloons (DCBs) have proven to be a suitable alternative for the treatment of cardiovascular diseases. They allow for uniform delivery of an antiproliferative drug to the stenotic site without permanent implantation of the device in the patient's body. There are, however, regulatory concerns regarding the lack of data associated with variable drug delivery to the target site, which can be related to the coating process. This study describes the process for an in-house micro-pipetting coating method that incorporates a laboratory-developed coating equation for determining optimal coating parameters. The coating solutions included a common drug of choice, paclitaxel, along with a hydrophilic excipient, such as iopromide. It was found that using a revolution rate of 240 rev/min, a flow rate of 25 µL/min and a translational speed of 0.033 cm/s resulted in visually uniform coatings. High performance liquid chromatography (HPLC) allowed for the determination of paclitaxel content on the balloon surface. Scanning electron microscopy (SEM) enabled analysis of coating thickness and texture at distal, middle, and proximal positions on the balloon; average thicknesses were determined to be 16.4 ±â€¯5.8, 14.8 ±â€¯1.4, and 18.1 ±â€¯3.9 µm, respectively. These optimized coating conditions have been confirmed by in vitro drug release kinetics studies. Overall this study generated a simple and reproducible micro-pipetting coating method for the sustained release of drugs from the drug coated balloons.


Subject(s)
Drug Delivery Systems , Excipients/chemistry , Iohexol/analogs & derivatives , Paclitaxel/administration & dosage , Angioplasty, Balloon, Coronary/instrumentation , Chemistry, Pharmaceutical/methods , Chromatography, High Pressure Liquid/methods , Delayed-Action Preparations , Drug Liberation , Iohexol/chemistry , Microscopy, Electron, Scanning/methods , Paclitaxel/chemistry , Reproducibility of Results , Technology, Pharmaceutical/methods
3.
J Biomed Mater Res B Appl Biomater ; 106(6): 2393-2402, 2018 08.
Article in English | MEDLINE | ID: mdl-29178263

ABSTRACT

Liners used in orthopedic devices are often made from ultrahigh molecular weight polyethylene (UHMWPE). A general predictive capability for transport coefficients of small molecules in UHMWPE does not exist, making it difficult to assess properties associated with leaching or uptake of small molecules. To address this gap, we describe here how a form of the Vrentas-Duda free volume model can be used to predict upper-bound diffusion coefficients (D) of arbitrary molecules within UHMWPE on the basis of their size and shape. Within this framework, the free-volume microstructure of UHMWPE is defined by analysis of a curated set of model diffusants. We determined an upper limit on D for vitamin E, a common antioxidant added to UHMWPE, to be 7.1 × 10-12 cm2  s-1 . This means that a liner that contains 0.1 wt % or less Vitamin E and has <120 cm2 patient contacting surface area would elute <100 µg/day of vitamin E. Additionally, the model predicts that squalene and cholesterol-two pro-oxidizing biological compounds-do not penetrate over 820 µm into UHMWPE liners over the course of 5 years because their D is ≤7.1 × 10-12 cm2  s-1 . © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 2393-2402, 2018.


Subject(s)
Coated Materials, Biocompatible/chemistry , Hip Prosthesis , Materials Testing , Polyethylenes/chemistry , Humans
4.
AAPS PharmSciTech ; 16(4): 811-23, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25563817

ABSTRACT

The drug coating process for coated drug-eluting stents (DES) has been identified as a key source of inter- and intra-batch variability in drug elution rates. Quality-by-design (QbD) principles were applied to gain an understanding of the ultrasonic spray coating process of DES. Statistically based design of experiments (DOE) were used to understand the relationship between ultrasonic atomization spray coating parameters and dependent variables such as coating mass ratio, roughness, drug solid state composite microstructure, and elution kinetics. Defect-free DES coatings composed of 70% 85:15 poly(DL-lactide-co-glycolide) and 30% everolimus were fabricated with a constant coating mass. The drug elution profile was characterized by a mathematical model describing biphasic release kinetics. Model coefficients were analyzed as a DOE response. Changes in ultrasonic coating processing conditions resulted in substantial changes in roughness and elution kinetics. Based on the outcome from the DOE study, a design space was defined in terms of the critical coating process parameters resulting in optimum coating roughness and drug elution. This QbD methodology can be useful to enhance the quality of coated DES.


Subject(s)
Drug-Eluting Stents , Ultrasonics , Chromatography, High Pressure Liquid , Everolimus/chemistry , Everolimus/pharmacokinetics , Microscopy, Atomic Force , Microscopy, Electron, Scanning , Polyglactin 910 , Surface Properties
5.
J Biomech Eng ; 136(2): 021027, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24317017

ABSTRACT

The objective of this study is to develop a theoretical model to simulate temperature fields in a joint simulator for various bearing conditions using finite element analyses. The frictional heat generation rate at the interface between a moving pin and a stationary base is modeled as a boundary heat source. Both the heat source and the pin are rotating on the base. We are able to conduct a theoretical study to show the feasibility of using the COMSOL software package to simulate heat transfer in a domain with moving components and a moving boundary source term. The finite element model for temperature changes agrees in general trends with experimental data. Heat conduction occurs primarily in the highly conductive base component, and high temperature elevation is confined to the vicinity of the interface in the pin. Thirty rotations of a polyethylene pin on a cobalt-chrome base for 60 s generate more than 2.26 °C in the temperature elevation from its initial temperature of 25 °C at the interface in a baseline model with a rotation frequency of 0.5 Hz. A higher heat generation rate is the direct result of a faster rotation frequency associated with intensity of exercise, and it results in doubling the temperature elevations when the frequency is increased by100%. Temperature elevations of more than 7.5 °C occur at the interface when the friction force is tripled from that in the baseline model. The theoretical modeling approach developed in this study can be used in the future to test different materials, different material compositions, and different heat generation rates at the interface under various body and environmental conditions.


Subject(s)
Computer-Aided Design , Energy Transfer , Equipment Failure Analysis/instrumentation , Equipment Failure Analysis/methods , Hip Prosthesis , Models, Theoretical , Temperature , Computer Simulation , Friction , Thermal Conductivity
6.
J Biomed Mater Res B Appl Biomater ; 101(7): 1191-9, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23564439

ABSTRACT

Drug-polymer composite coatings, composed of styrene-isobutylene-styrene (SIBS) tri-block copolymers, are frequently used in controlled drug release biomedical device applications. In this work, we used atomic force microscopy to characterize the effects of different drug loadings and polymer chemistries (i.e., block copolymer ratio) on the variation of surface structures and compositions of SIBS-tetracycline (SIBS-TC) cast composites including tetracycline (TC) drug amount, drug phase size distribution, and drug and polymer phase morphologies. We tested the structural variations by fabricating and characterizing two types of composite specimens, that is, SIBS15 and SIBS30, composed of 15 and 30 Wt % of polystyrene (PS), respectively. The differences in the distribution of TC drug, PS, and polyisobutylene (PIB) polymer phase structures observed in SIBS15 and SIBS30 resulted in more drug at the surface of SIBS30 compared to SIBS15. To support the experimental findings, we have determined the Hildebrand solubility parameter of TC using molecular dynamics (MD) computation and compared it to the polymer components, PS and PIB. The MD results show that the solubility parameter of TC is much closer to that of PS than PIB, which demonstrates a higher thermodynamic stability of TC-PS mixtures.


Subject(s)
Anti-Bacterial Agents/chemistry , Drug Delivery Systems , Styrenes/chemistry , Tetracycline/chemistry
7.
Antimicrob Agents Chemother ; 55(5): 2166-73, 2011 May.
Article in English | MEDLINE | ID: mdl-21383096

ABSTRACT

GS-9191, a bis-amidate prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine (cPrPMEDAP), was designed as a topical agent for the treatment of papillomavirus-associated proliferative disorders, such as genital warts. In this study, we investigated the mechanism of conversion of GS-9191 to cPrPMEDAP. We observed that GS-9191 is hydrolyzed in the presence of the lysosomal carboxypeptidase cathepsin A (CatA) in vitro and is less efficiently metabolized in CatA-deficient fibroblasts than in control cells. In addition, knockdown of CatA by small interfering RNA (siRNA) reduced the intracellular accumulation of GS-9191 metabolites. However, intracellular CatA levels did not correlate with the susceptibility of tested cell lines to GS-9191, indicating that the CatA step is unlikely to be rate limiting for the activation of GS-9191. Further analysis showed that upon the hydrolysis of the carboxylester bond in one of the GS-9191 amidate moieties, the unmasked carboxyl group displaces L-phenylalanine 2-methylpropyl ester from the other amidate moiety. The cPrPMEDAP-L-phenylalanine conjugate (cPrPMEDAP-Phe) formed is not metabolized by Hint1 (histidine triad nucleotide binding protein 1) phosphoramidase but undergoes spontaneous degradation to cPrPMEDAP in acidic pH that can be significantly enhanced by the addition of SiHa cell extract. Pretreatment of SiHa cells with bafilomycin A or chloroquine resulted in an 8-fold increase in the intracellular concentration of cPrPMEDAP-Phe metabolite and the accumulation of GS-9191 metabolites in the lysosomal/endosomal fraction. Together, these observations indicate that the conversion of GS-9191 to cPrPMEDAP occurs in lysosomes via CatA-mediated ester cleavage, followed by the release of cPrPMEDAP, most likely through the combination of enzyme-driven and spontaneous pH-driven hydrolysis of a cPrPMEDAP-Phe intermediate.


Subject(s)
Antiviral Agents/pharmacology , Cathepsin A/metabolism , Lysosomes/metabolism , Papillomaviridae/drug effects , Papillomaviridae/metabolism , Phenylalanine/analogs & derivatives , Antiviral Agents/metabolism , Cathepsin A/genetics , Cell Line, Tumor , Chloroquine/pharmacology , Female , HeLa Cells , Humans , Hydrogen-Ion Concentration , Immunoblotting , Macrolides/pharmacology , Papillomaviridae/genetics , Phenylalanine/metabolism , Phenylalanine/pharmacology , Uterine Cervical Neoplasms/virology
8.
Bioorg Med Chem ; 18(10): 3606-17, 2010 May 15.
Article in English | MEDLINE | ID: mdl-20409721

ABSTRACT

GS-9148 [(5-(6-amino-purin-9-yl)-4-fluoro-2,5-dihydro-furan-2-yloxymethyl)phosphonic acid] 4 is a novel nucleoside phosphonate HIV-1 reverse transcriptase (RT) inhibitor with a unique resistance profile toward N(t)RTI resistance mutations. To effectively deliver 4 and its active phosphorylated metabolite 15 into target cells, a series of amidate prodrugs were designed as substrates of cathepsin A, an intracellular lysosomal carboxypeptidase highly expressed in peripheral blood mononuclear cells (PBMCs). The ethylalaninyl phosphonamidate prodrug 5 (GS-9131) demonstrated favorable cathepsin A substrate properties, in addition to favorable in vitro intestinal and hepatic stabilities. Following oral dosing (3mg/kg) in Beagle dogs, high levels (>9.0microM) of active metabolite 15 were observed in PBMCs, validating the prodrug design process and leading to the nomination of 5 as a clinical candidate.


Subject(s)
Adenine/analogs & derivatives , Anti-HIV Agents/pharmacology , Guanosine/analogs & derivatives , HIV-1/drug effects , Reverse Transcriptase Inhibitors/pharmacology , Adenine/chemical synthesis , Adenine/pharmacology , Animals , Anti-HIV Agents/chemical synthesis , Anti-HIV Agents/chemistry , CD4-Positive T-Lymphocytes/drug effects , Dogs , Drug Design , Drug Resistance, Viral/drug effects , Drug Stability , Guanosine/pharmacology , Nucleosides/pharmacology , Organophosphonates/pharmacology , Prodrugs/metabolism , Prodrugs/pharmacology , Reverse Transcriptase Inhibitors/chemical synthesis , Tumor Cells, Cultured
9.
J Pharm Sci ; 99(6): 2777-85, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20091828

ABSTRACT

A critical metrology issue for pharmaceutical industries is the application of analytical techniques for the characterization of drug delivery systems to address interrelationships between processing, structure, and drug release. In this study, cast coatings were formed from solutions of poly(styrene-b-isobutylene-b-styrene) (SIBS) and tetracycline in tetrahydrofuran (THF). These coatings were characterized by several imaging modalities, including time-of-flight secondary ion mass spectrometry (TOF-SIMS) for chemical imaging and analysis, atomic force microscopy (AFM) for determination of surface structure and morphology, and laser scanning confocal microscopy (LSCM), which was used to characterize the three-dimensional structure beneath the surface. The results showed phase separation between the drug and copolymer regions. The size of the tetracycline phase in the polymer matrix ranged from hundreds of nanometers to tens of microns, depending on coating composition. The mass of drug released was not found to be proportional to drug loading, because the size and spatial distribution of the drug phase varied with drug loading and solvent evaporation rate, which in turn affected the amount of drug released.


Subject(s)
Drug Delivery Systems , Pharmaceutical Preparations/analysis , Polymers/chemistry , Solvents/chemistry , Spectrometry, Mass, Secondary Ion/methods , Anti-Bacterial Agents , Dosage Forms , Microscopy, Atomic Force , Styrenes , Tetracycline
10.
J Biomed Mater Res B Appl Biomater ; 90(2): 688-99, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19213052

ABSTRACT

To improve functionality and performance, controlled drug-release coatings comprised of drug and polymer are integrated with traditional medical devices, e.g., drug eluting stents. Depending on manufacturing conditions, these coatings can exhibit complex microstructures. Previously, a thermodynamically consistent model was developed for microstructure evolution in these systems to establish relationships between process variables, microstructure, and the subsequent release kinetics. Calculations based on the model were, in general, consistent with experimental findings. However, because of assumptions regarding the evaporation of solvent during fabrication, the model was unable to capture variations through the coating thickness that are observed experimentally. Here, a straightforward method is introduced to incorporate solvent evaporation explicitly into the model. Calculations are used to probe the impact of solvent evaporation rate and drug loading on the microstructure that forms during manufacturing and subsequent drug release kinetics. The predicted structures and release kinetics are found to be consistent with experimental observations. Further, the calculations demonstrate that solvent evaporation rate can be as critical to device performance as the amount of drug within the coating. For example, changes of a factor of five in the amount of drug released were observed by modifying the rate of solvent evaporation during manufacturing.


Subject(s)
Delayed-Action Preparations/pharmacology , Drug Delivery Systems , Solvents/chemistry , Anti-Bacterial Agents/administration & dosage , Chemistry, Pharmaceutical/methods , Coated Materials, Biocompatible , Computer Simulation , Drug Design , Kinetics , Microscopy, Confocal/methods , Models, Statistical , Reproducibility of Results , Tetracycline/administration & dosage , Thermodynamics
11.
Mol Pharmacol ; 74(1): 92-100, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18430788

ABSTRACT

9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) is an isopropylalaninyl phenyl ester prodrug of the nucleotide HIV reverse transcriptase inhibitor tenofovir (TFV; 9-[(2-phosphonomethoxy)propyl]adenine) exhibiting potent anti-HIV activity and enhanced ability to deliver parent TFV into peripheral blood mononuclear cells (PBMCs) and other lymphatic tissues in vivo. The present study focuses on the intracellular metabolism of GS-7340 and its activation by a variety of cellular hydrolytic enzymes. Incubation of human PBMCs in the presence of GS-7340 indicates that the prodrug is hydrolyzed slightly faster to an intermediate TFV-alanine conjugate (TFV-Ala) in quiescent PBMCs compared with activated cells (0.21 versus 0.16 pmol/min/10(6) cells). In contrast, the conversion of TFV-Ala to TFV and subsequent phosphorylation to TFV-diphosphate occur more rapidly in activated PBMCs. The activity of GS-7340 hydrolase producing TFV-Ala in PBMCs is primarily localized in lysosomes and is sensitive to inhibitors of serine hydrolases. Cathepsin A, a lysosomal serine protease has recently been identified as the primary enzyme activating GS-7340 in human PBMCs. Results from the present study indicate that in addition to cathepsin A, a variety of serine and cysteine proteases cleave GS-7340 and other phosphonoamidate prodrugs of TFV. The substrate preferences displayed by these enzymes toward TFV amidate prodrugs are nearly identical to their preferences displayed against oligopeptide substrates, indicating that GS-7340 and other phosphonoamidate derivatives of TFV should be considered peptidomimetic prodrugs of TFV.


Subject(s)
Adenine/analogs & derivatives , Anti-HIV Agents/metabolism , Organophosphonates/metabolism , Peptide Hydrolases/metabolism , Prodrugs/metabolism , Adenine/chemistry , Adenine/metabolism , Adenine/pharmacology , Alanine , Anti-HIV Agents/pharmacology , Biomarkers/analysis , Cathepsin A/metabolism , Cells, Cultured , Enzyme Activation , Humans , Hydrolysis , Kinetics , Leukocytes, Mononuclear/metabolism , Lysosomes/enzymology , Lysosomes/metabolism , Molecular Structure , Organophosphonates/pharmacology , Peptide Hydrolases/pharmacology , Prodrugs/pharmacology , Reverse Transcriptase Inhibitors/metabolism , Reverse Transcriptase Inhibitors/pharmacology , Serine Endopeptidases/metabolism , Subcellular Fractions , Substrate Specificity , Tenofovir , beta-N-Acetylhexosaminidases/analysis
12.
Antimicrob Agents Chemother ; 51(8): 2911-9, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17517852

ABSTRACT

The ATP-dependent phosphorolytic excision of nucleoside analogue reverse transcriptase inhibitors can diminish their inhibitory effects on human immunodeficiency virus replication. Previous studies have shown that excision can occur only when the reverse transcriptase complex exists in its pretranslocational state. Binding of the next complementary nucleotide causes the formation of a stable dead-end complex in the posttranslocational state, which blocks the excision reaction. To provide mechanistic insight into the excision of the acyclic phosphonate nucleotide analog tenofovir, we compared the efficiencies of the reaction in response to changes in the translocation status of the enzyme. We found that rates of excision of tenofovir with wild-type reverse transcriptase can be as high as those seen with 3'-azido-3'-deoxythymidine monophosphate (AZT-MP). Thymidine-associated mutations, which confer >100-fold and 3-fold decreased susceptibility to AZT and tenofovir, respectively, caused substantial increases in the efficiency of excision of both inhibitors. However, in contrast to the case for AZT-MP, the removal of tenofovir was highly sensitive to dead-end complex formation. Site-specific footprinting experiments revealed that complexes with AZT-terminated primers exist predominantly pretranslocation. In contrast, complexes with tenofovir-terminated primers are seen in both configurations. Low concentrations of the next nucleotide are sufficient to trap the complex posttranslocation despite the flexible, acyclic character of the compound. Thus, the relatively high rate of excision of tenofovir is partially neutralized by the facile switch to the posttranslocational state and by dead-end complex formation, which provides a degree of protection from excision in the cellular environment.


Subject(s)
Adenine/analogs & derivatives , Anti-HIV Agents/metabolism , HIV Reverse Transcriptase/metabolism , HIV-1/drug effects , Organophosphonates/metabolism , Reverse Transcriptase Inhibitors/metabolism , Adenine/metabolism , Adenine/pharmacology , Adenosine Triphosphate/metabolism , Anti-HIV Agents/pharmacology , Base Sequence , Drug Resistance, Viral , HIV Reverse Transcriptase/genetics , HIV-1/enzymology , HIV-1/genetics , Humans , Kinetics , Microbial Sensitivity Tests , Molecular Sequence Data , Organophosphonates/pharmacology , Reverse Transcriptase Inhibitors/pharmacology , Tenofovir , Zidovudine/analogs & derivatives , Zidovudine/chemistry , Zidovudine/metabolism , Zidovudine/pharmacology
13.
Biochemistry ; 46(10): 2899-908, 2007 Mar 13.
Article in English | MEDLINE | ID: mdl-17298035

ABSTRACT

LEDGF/p75 is known to enhance the integrase strand transfer activity in vitro, but the underlying mechanism is unclear. Using an integrase assay with a chemiluminescent readout adapted to a 96-well plate format, the effect of LEDGF/p75 on both the 3'-processing and strand transfer steps was analyzed. Integrase inhibitors of the strand transfer reaction remained active in the presence of LEDGF/p75, but displayed 3- to 7-fold higher IC50 values. Our analyses indicate that, in the presence of 150 nM LEDGF/p75, active integrase/donor DNA complexes were increased by 5.3-fold during the 3'-processing step. In addition, these integrase/donor DNA complexes showed a 4.5-fold greater affinity for the target DNA during the subsequent strand transfer step. We also observed a 3.7-fold increase in the rate constant of catalysis of the strand transfer step when 150 nM LEDGF/p75 was present during the 3'-processing step. In contrast, when LEDGF/p75 was added at the beginning of the strand transfer step, no increase in either the concentration of active integrase/donor DNA complex or its rate constant of strand transfer catalysis was observed. This observation suggested that the integrase/donor DNA formed in the absence of LEDGF/p75 became refractory to the stimulatory effect of LEDGF/p75. Instead, this LEDGF/p75 added at the start of the strand transfer step was able to promote the formation of a new cohort of active integrase/donor DNA complexes which became functional with a delay of 45 min after LEDGF/p75 addition. We propose a model whereby LEDGF/p75 can only bind integrase before the latter binds donor DNA whereas donor DNA can engage either free or LEDGF/p75-bound integrase.


Subject(s)
DNA/metabolism , HIV Integrase/metabolism , HIV-1/enzymology , Intercellular Signaling Peptides and Proteins/pharmacology , DNA/drug effects , Enzyme Activation/drug effects , Enzyme Activation/physiology , Macromolecular Substances/metabolism
14.
Antimicrob Agents Chemother ; 51(2): 543-50, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17145787

ABSTRACT

GS-7340 and GS-9131 {9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]-propyl]adenine and 9-(R)-4'-(R)-[[[(S)-1-[(ethoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]-2'-fluoro-1'-furanyladenine, respectively} are novel alkylalaninyl phenyl ester prodrugs of tenofovir {9-R-[(2-phosphonomethoxy)propyl]adenine} (TFV) and a cyclic nucleotide analog, GS-9148 (phosphonomethoxy-2'-fluoro-2', 3'-dideoxydidehydroadenosine), respectively. Both prodrugs exhibit potent antiretroviral activity against both wild-type and drug-resistant human immunodeficiency virus type 1 strains and excellent in vivo pharmacokinetic properties. In this study, the main enzymatic activity responsible for the initial step in the intracellular activation of GS-7340 and GS-9131 was isolated from human peripheral blood mononuclear cells and identified as lysosomal carboxypeptidase A (cathepsin A [CatA]; EC 3.4.16.5). Biochemical properties of the purified hydrolase (native complex and catalytic subunit molecular masses of 100 and 29 kDa, respectively; isoelectric point [pI] of 5.5) matched those of CatA. Recombinant CatA and the isolated prodrug hydrolase displayed identical susceptibilities to inhibitors and identical substrate preferences towards a panel of tenofovir phosphonoamidate prodrugs. Incubation of both enzymes with 14C-labeled GS-7340 or [3H]difluorophosphonate resulted in the covalent labeling of identical 29-kDa catalytic subunits. Finally, following a 4-h incubation with GS-7340 and GS-9131, the intracellular concentrations of prodrug metabolites detected in CatA-negative fibroblasts were approximately 7.5- and 3-fold lower, respectively, than those detected in normal control fibroblasts. Collectively, these data demonstrate the key role of CatA in the intracellular activation of nucleotide phosphonoamidate prodrugs and open new possibilities for further improvement of this important class of antiviral prodrugs.


Subject(s)
Adenine/analogs & derivatives , Cathepsin A/metabolism , Prodrugs/metabolism , Adenine/metabolism , Adenine/pharmacology , Alanine , Anti-Retroviral Agents/metabolism , Anti-Retroviral Agents/pharmacology , Catalysis , Cell Size/drug effects , Cells, Cultured , Enzyme Activation , Fibroblasts/cytology , Fibroblasts/metabolism , Humans , Hydrolysis , Kinetics , Monocytes/metabolism , Prodrugs/pharmacology , Recombinant Proteins/metabolism , Substrate Specificity , Tenofovir/analogs & derivatives
15.
J Mol Biol ; 363(3): 635-47, 2006 Oct 27.
Article in English | MEDLINE | ID: mdl-16979654

ABSTRACT

The introduction of human immunodeficiency virus type 1 (HIV-1) protease inhibitors (PIs) markedly improved the clinical outcome and control of HIV-1 infection. However, cross-resistance among PIs due to a wide spectrum of mutations in viral protease is a major factor limiting their broader clinical use. Here we report on the suppression of PI resistance using a covalent attachment of a phosphonic acid motif to a peptidomimetic inhibitor scaffold. The resulting phosphonate analogs maintain high binding affinity to HIV-1 protease, potent antiretroviral activity, and unlike the parent molecules, display no loss of potency against a panel of clinically important PI-resistant HIV-1 strains. As shown by crystallographic analysis, the phosphonate moiety is highly exposed to solvent with no discernable interactions with any of the enzyme active site or surface residues. We term this effect "solvent anchoring" and demonstrate that it is driven by a favorable change in the inhibitor binding entropy upon the interaction with mutant enzymes. This type of thermodynamic behavior, which was not found with the parent scaffold fully buried in the enzyme active site, is a result of the increased degeneracy of inhibitor binding states, allowing effective molecular adaptation to the expanded cavity volume of mutant proteases. This strategy, which is applicable to various PI scaffolds, should facilitate the design of novel PIs and potentially other antiviral therapeutics.


Subject(s)
Drug Design , Drug Resistance, Multiple, Viral , HIV Protease Inhibitors/chemistry , HIV Protease/chemistry , Organophosphonates/chemistry , Solvents , Atazanavir Sulfate , Binding Sites , HIV Infections/drug therapy , HIV Protease/metabolism , HIV Protease Inhibitors/metabolism , HIV Protease Inhibitors/therapeutic use , Humans , Models, Molecular , Molecular Structure , Oligopeptides/chemistry , Oligopeptides/metabolism , Pyridines/chemistry , Pyridines/metabolism , Thermodynamics
16.
Acta Biomater ; 2(5): 537-46, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16844438

ABSTRACT

Hematopoietic stem cell (HSC) therapy can significantly lower instances of infection in chemotherapy patients by accelerating the recovery of white blood cells in the body. However, therapy requires that HSCs be stored at cryogenic temperatures to retain the cells' ability to proliferate. Currently, cells are stored in polymeric blood bags that are subject to fracture at the extremely low storage temperatures, which leads to cell contamination, thereby reducing their effectiveness. Therefore, we have developed an analytical model to predict the accumulation of stresses that ultimately lead to crack initiation and bag fracture during cryogenic storage. Our model gives explicit relationships between stress state in the container and thermoelastic properties of the container material, container geometry, and environmental factors that include temperature of the system and pressure induced by excess gas evolving from the stored medium. Predictions based on the model are consistent with experimental observations of bag failures that occurred during cryogenic storage applications. Finally, the model can provide guidance in material selection and bag design to fabricate bags that will be less susceptible to fracture.


Subject(s)
Cryopreservation/methods , Hematopoietic Stem Cells , Antineoplastic Agents/adverse effects , Biocompatible Materials , Cryopreservation/instrumentation , Elasticity , Equipment Design , Hematopoietic Stem Cell Transplantation , Humans , In Vitro Techniques , Leukopenia/chemically induced , Leukopenia/therapy , Materials Testing , Models, Theoretical , Neoplasms/drug therapy , Neoplasms/therapy , Polymers , Stress, Mechanical , Transplantation, Autologous
17.
Antivir Ther ; 11(2): 155-63, 2006.
Article in English | MEDLINE | ID: mdl-16640096

ABSTRACT

The HIV-1 nucleoside reverse transcriptase inhibitors (NRTIs) tenofovir (TFV), abacavir, didanosine and stavudine can select for K65R, whereas zidovudine (AZT) and stavudine can select for thymidine analogue mutations (TAMs) in HIV-1 reverse transcriptase (RT). HIV-1 with TAMs shows reduced susceptibility to all NRTIs, most notably AZT, whereas HIV-1 with K65R shows reduced susceptibility to all NRTIs except AZT. K65R and TAMs rarely occur together in patients. However, when present together, K65R can restore susceptibility to AZT. This study characterizes the underlying mechanisms of resistance of these RT mutants to TFV and AZT. K65R mediated decreased binding/incorporation of TFV and AZT (increased Ki/Km of 7.1- and 4.3-fold, respectively), but also decreased excision of TFV and AZT (0.7- and 0.3-fold, respectively) when compared with wild-type RT. By contrast, TAMs mediated increased TFV and AZT excision (11- and 5.4-fold, respectively), and showed no changes in binding/incorporation. When these mutations were combined, K65R reversed TAM-mediated AZT resistance by strongly reducing AZT excision. Molecular modelling studies suggest that K65R creates additional hydrogen bonds that reduce the conformational mobility of RT, resulting in reduced polymerization and excision. Thus, consistent with clinical HIV-1 genotyping data, there appears to be no net NRTI resistance benefit for TAMs and K65R to develop together in patients taking AZT and TFV disoproxil fumarate, where the TAM pathway alone provides the greatest resistance for both drugs.


Subject(s)
Drug Resistance, Viral/genetics , HIV Reverse Transcriptase/genetics , HIV-1/drug effects , HIV-1/enzymology , Mutation/genetics , Zidovudine/pharmacology , Cell Line , HIV-1/genetics , Humans , Models, Molecular , Phenotype , Protein Binding , Reverse Transcriptase Inhibitors/pharmacology
18.
J Biomed Mater Res B Appl Biomater ; 77(2): 416-22, 2006 May.
Article in English | MEDLINE | ID: mdl-16278851

ABSTRACT

An adhesive that cures under moist/wet conditions could facilitate surgical procedures for retinal reattachment. We are investigating an adhesive that mimics the factor XIIIa-mediated crosslinking of fibrin that occurs in the late stages of the blood coagulation cascade. Specifically, we use gelatin as the structural protein (in place of fibrin), and crosslink gelatin using a calcium-independent microbial transglutaminase (in place of the calcium-dependent transglutaminase factor XIIIa). Injection of gelatin and microbial transglutaminase (mTG) into the vitreous cavity of Sprague Dawley white rats did not elicit structural or cellular damage to the retina as evidenced from histological evaluation 2 weeks post-injection. Qualitative in vitro studies indicate that the gelatin-mTG adhesive binds to bovine retinal tissue under wet conditions. Quantitative lap-shear tests were performed with more robust bovine tissue from the choroid and sclera. The lap-shear strength of the biomimetic gelatin-mTG adhesive was independent of tissue-type and ranged from 15 to 45 kPa, which is comparable to the values reported for other soft-tissue adhesives. These studies suggest that the mTG-crosslinked gelatin may provide a simple, safe, and effective adhesive for ophthalmic applications.


Subject(s)
Gelatin/administration & dosage , Retinal Detachment/therapy , Tissue Adhesives/chemistry , Adhesiveness , Animals , Biomimetic Materials , Cattle , Factor XIIIa/administration & dosage , Factor XIIIa/metabolism , Gelatin/chemical synthesis , Injections , Rats , Rats, Sprague-Dawley , Retina , Shear Strength
19.
AIDS ; 19(16): 1751-60, 2005 Nov 04.
Article in English | MEDLINE | ID: mdl-16227782

ABSTRACT

OBJECTIVE: To determine the mechanisms of resistance of K65R mutant reverse transcriptase (RT) to the currently approved nucleoside and nucleotide RT inhibitors (NRTI). METHODS: Susceptibilities of K65R mutant HIV-1 to NRTI were determined in cell culture. The Ki/Km values were measured to determine the relative binding or incorporation of the NRTI, and ATP-mediated excision of incorporated NRTI was measured to determine NRTI stability as chain terminators. RESULTS: K65R HIV-1 had decreased susceptibility to most NRTI, but increased susceptibility to zidovudine (ZDV). Ki/Km values were increased 2- to 13-fold for K65R compared to wild-type RT for all NRTI, indicating decreased binding or incorporation. However, K65R also showed decreased excision of all NRTI compared to wild-type, indicating greater stability once incorporated. At physiological nucleotide concentrations, excision of ZDV, carbovir (the active metabolite of abacavir; ABC), stavudine (d4T), and tenofovir was further decreased, while excision of didanosine (ddI), zalcitabine (ddC), lamivudine (3TC), and emtricitabine (FTC) was unchanged. The decreased binding or incorporation of ZDV by K65R appeared counteracted by decreased excision resulting in overall increased susceptibility to ZDV in cell culture. For ABC, tenofovir, and d4T, despite having decreased excision, decreased binding or incorporation resulted in reduced susceptibilities to K65R. For ddI, ddC, 3TC, and FTC, decreased binding or incorporation by K65R appeared responsible for the decreased susceptibilities in cell culture. CONCLUSIONS: NRTI resistance in cells can consist of both altered binding or incorporation and altered excision of the NRTI. For K65R, the combination of these opposing mechanisms results in decreased susceptibility to most NRTI but increased susceptibility to ZDV.


Subject(s)
Anti-HIV Agents/therapeutic use , Drug Resistance, Viral/genetics , HIV Infections/drug therapy , HIV Reverse Transcriptase/genetics , HIV-1/genetics , Reverse Transcriptase Inhibitors/therapeutic use , Cells, Cultured , HIV Reverse Transcriptase/antagonists & inhibitors , Humans , Microbial Sensitivity Tests , Mutation/genetics
20.
Biomacromolecules ; 5(4): 1270-9, 2004.
Article in English | MEDLINE | ID: mdl-15244440

ABSTRACT

Fibrin sealants are a type of soft tissue adhesive that employs biochemical reactions from the late stages of the blood coagulation cascade. Intrinsic to these adhesives are a structural protein and a transglutaminase crosslinking enzyme. We are investigating an alternative biomimetic adhesive based on gelatin and a calcium-independent microbial transglutaminase (mTG). Rheological measurements show that mTG catalyzes the conversion of gelatin solutions into hydrogels, and gel times are on the order of minutes depending on the gelatin type and concentration. Tensile static and dynamic loading of the adhesive hydrogels in bulk form demonstrated that the Young's modulus ranged from 15 to 120 kPa, and these bulk properties were comparable to those reported for hydrogels obtained from fibrin-based sealants. Lap-shear adhesion tests of porcine tissue were performed using a newly published American Society for Testing and Materials (ASTM) standard for tissue adhesives. The gelatin-mTG adhesive bound the opposing tissues together with ultimate adhesive strengths of 12-23 kPa which were significantly higher than the strength observed for fibrin sealants. Even after failure, strands of the gelatin-mTG adhesive remained attached to both of the opposing tissues. These results suggest that gelatin-mTG adhesives may offer the benefits of fibrin sealants without the need for blood products.


Subject(s)
Biomimetic Materials/chemistry , Cross-Linking Reagents/chemistry , Gelatin/chemistry , Tissue Adhesives/chemistry , Transglutaminases/chemistry , Animals , Catalysis , Elasticity , Fibrin Tissue Adhesive/chemistry , Humans , Hydrogel, Polyethylene Glycol Dimethacrylate/chemistry , In Vitro Techniques , Materials Testing , Rheology , Stress, Mechanical , Swine , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...